在新诊断出血性恶性瘤的儿科患者中出现伪高血症
Ting-Chu Li1, Wei-Cheng Chan2, Ming-Chin Tsai1
1Division of Nephrology, Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan.
Pediatric hematology and oncology
|June 13, 2024
概括
伪超卡莱米亚是一种实验室人工物,发生在4.5%的儿科血性恶性瘤患者中,在超白细胞症中增加到21.2%. 早期识别可以防止不必要的治疗.
科学领域:
- 儿科血液学 儿科血液学
- 临床病理学 临床病理学
- 在瘤学瘤学.
背景情况:
- 血液性恶性瘤可能会导致高细胞负担导致高胆固醇血症.
- 由于体外细胞溶解引起的伪高血症使诊断复杂化.
- 在儿科患者中发生的情况报告不足.
研究的目的:
- 确定新诊断出血性恶性瘤的儿科患者中伪高血症的发生率.
- 在这个人群中识别与伪高血症相关的因素.
主要方法:
- 儿科患者病历的回顾性审查 (2011-2022年).
- 确定的高卡利米亚 (>5.5 mEq/L) 和伪高卡利米亚 (下降>1 mEq/L在4小时内或没有心电图变化).
- 排除了明显红细胞血解的病例.
主要成果:
- 包括157名儿科患者;14名患有高血症.
- 7例 (4.5%) 被确定为伪高血症.
- 在患有超白细胞瘤的患者中,发病率上升至21.2%.
- 与较高的白血细胞和较低的相关的伪超卡莱米亚;发生在ED的血样本中.
- 在病房/ICU和血清样本中发生了真正的高血症.
结论:
- 伪高血是小儿血液恶性瘤中未被认可的问题.
- 较高的初始白细胞计数和较低的血清是相关因素.
- 样品类型 (血与血清) 和采集位置 (ED与病房/ICU) 可能会影响检测.
- 及时识别至关重要,以避免不必要的干预.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.3K
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
512
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
512
Bone Marrow Sampling and Transplants
324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
